Abstracts tagged "Lupus"

Abstract Number: 1245 • 2015 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Lupus Nephritis Shows Enrichment in Genes Involved in Regulation of TH2 Differentiation and Renal Development
Renuka Nayak¹, Sharon A. Chung², Joanne Nitiham³ and Lindsey A. Criswell³, ¹Department of Medicine, UCSF, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ²Russell/Englemen Rheumatology Research Center, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ³Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE). We have the ability to identify these factors and their influence…
Abstract Number: 1934 • 2015 ACR/ARHP Annual Meeting
Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus
Maud Wilhelm¹, Fengjuan Wang², Nicolas Schall², Michael Faludi³, Jean Francois Kleinmann⁴, Emil P. Nashi⁵, Thierry Martin⁶, Jean Sibilia⁷, Jean-Louis Pasquali⁸, Daniel Wallace⁹ and Sylviane Muller¹⁰, ¹Immunopathologie & Chimie Thérapeutique, CNRS, Strasbourg, France, ²CNRS, Strasbourg, France, ³761 Graham, McGill University, Mont-Royal, QC, Canada, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Cnrs UPR9021, IBMC, Strasbourg, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁸Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ⁹Cedars-Sinai/UCLA, Los Angeles, CA, ¹⁰CNRS Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
Background/Purpose: P140 is a 21-mer peptide (sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K. In a multicenter, randomized, placebo-controlled…
Abstract Number: 3160 • 2015 ACR/ARHP Annual Meeting
Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Daniel H. Solomon¹, Seoyoung C. Kim⁶ and Karen H. Costenbader⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk of infections partly from use of immunosuppressives (IS). Clinical trials are powered to detect…
Abstract Number: 392 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Lily Siok Hoon Lim^1,2,3,4, Eleanor Pullenayegum⁵, Lillian Lim⁶, Dafna Gladman⁷, Brian Feldman⁸ and Earl Silverman⁹, ¹Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Rheumatology, SickKids, Toronto, ON, Canada, ³Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ⁵Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Outcomes of patients with cSLE over time and into adulthood are poorly understood. There has been no information about the longitudinal trajectory of organ…
Abstract Number: 788 • 2015 ACR/ARHP Annual Meeting
Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies
Matteo Cesaroni¹, Jarrat Jordan¹, Jessica Schreiter¹, Marc Chevrier¹, Grace Wang², Cesar Calderon³, Alexa Piantone², Ian Gourley⁴, Stanley Cohen⁵, Scott Fretzin⁶, Anna Wozniacka⁷, Victoria P. Werth⁸ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, Spring House, PA, ³37 Derwen Dr., Janssen Research and Development, Havertown, PA, ⁴1329 Anthony Wayne drive, Janssen Research and Development, Wayne, PA, ⁵Metroplex Clinical Research Center, LLC, Dallas, TX, ⁶Dawes Fretzin Clinical Research Group, LLCC, Indianapolis, IN, ⁷Medical University of Lodz, Lodz, Poland, ⁸Philadelphia VA Medical Center, Philadelphia, PA
Background/Purpose: Sub-classification of Lupus Erythematosus (LE) patients is largely based on defined clinical criteria while biological factors associating with or contributing to these clinical features…
Abstract Number: 1249 • 2015 ACR/ARHP Annual Meeting
Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells
Carolina Duarte¹, Lora Boteva², Timothy Vyse¹ and Michelle Fernando¹, ¹Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ²MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic autoimmune disease characterized by autoantibody production and up-regulation of type 1 interferons (IFNs). The strongest genetic association…
Abstract Number: 2074 • 2015 ACR/ARHP Annual Meeting
Dominant Chilblain Lupus Due to an Activating Mutation of Sting – Suppression of Constitutive Type I Interferon Activation By JAK Inhibition
Christoph Fiehn¹, Nadja König², Christine Wolf², Mathias Lesche³, Andreas Dahl³, Claudia Guenther⁴, Hanns-Martin Lorenz⁵ and Min Ae Lee-Kirsch², ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ³Department of Dermatology, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Biotechnology Center, Technische Universität Dresden, Dresden, Germany, ⁵Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany
Background/Purpose: Familial chilblain lupus is a monogenic form of cutaneous lupus erythematosus caused by mutations in the nucleases TREX1 or SAMHD1. The adapter molecule stimulator…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
Abstract Number: 393 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients
Lily Siok Hoon Lim¹, Eleanor Pullenayegum², Lillian Lim³, Dafna Gladman⁴, Brian Feldman⁵ and Earl Silverman⁶, ¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ³Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Although SLE patients are thought to follow different patterns of disease courses, no information is available about the longitudinal disease activity or the number…
Abstract Number: 799 • 2015 ACR/ARHP Annual Meeting
Transcriptional Profiling of Cutaneous Lupus Reveals Pronounced Changes in Keratinocyte and Myeloid Lineage Expressed Genes and Demonstrates Uniquely Regulated Interferon Pathways Between Rash Subtypes
Celine C. Berthier¹, Jasmine Stannard², Emily Myers³, William Swindell⁴, Lori Lowe⁴, Tamra J. Reed⁵, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁶, ¹Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ²Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, Georgetown University, Washington, DC, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus rashes can be substantial, disfiguring, and often refractory to usual lupus therapies. Phenotypic presentation and risk of systemic lupus manifestations differs by…
Abstract Number: 1752 • 2015 ACR/ARHP Annual Meeting
Characterization of Epitopes Identified with Cerebral Vasculature Injury
Melissa Butts¹, Jess Edison¹, Christopher Tracy¹, Brian Stout¹, Huazhen Chen² and Chantal Moratz², ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Medicine, Uniformed Services University School of Health Sciences, Bethesda, MD
Background/Purpose: There is an association between natural antibodies, such as anti-phospholipid antibodies, and vasculature injury in stroke and in SLE models of systemic ischemic damage. …
Abstract Number: 2080 • 2015 ACR/ARHP Annual Meeting
Teaching Fellows in Lupus: Rheumatology Fellows Are Successful Educators in Improving Lupus Recognition By Frontline Healthcare Providers
Amy Caron¹, S. Sam Lim², Lexi Rene³, Diane Gross⁴, Maria Dall'Era⁵, Rosalind Ramsey-Goldman⁶ and Amanda Sammut⁷, ¹Lupus Research Institute, New York City, NY, ²Emory University School of Medicine, Atlanta, GA, ³Rollins School of Public Health, Emory University, Atlanta, GA, ⁴S.L.E. Lupus Foundation/Lupus Research Institute, New York, NY, ⁵University of California San Francisco School of Medicine, San Francisco, CA, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Columbia University Medical Center and Harlem Hospital Center, New York, NY
Background/Purpose: The heterogeneity and non-specific features of lupus may delay diagnosis. This delay can lead to accrual of organ damage and an increased risk of…
Abstract Number: 3222 • 2015 ACR/ARHP Annual Meeting
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Chris Chamberlain¹, Murray Urowitz^2,3, Julie Soranson¹, Mark Watling¹, Peter Colman¹, Olivier Harari¹, Thomas Dorner⁴ and Falk Hiepe⁴, ¹UCB Pharma, Slough, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: CD40 ligand (CD40L) regulates interactions between T cells, B cells, and antigen presenting cells. Considerable evidence suggests CD40L blockade might provide an effective treatment…
Abstract Number: 397 • 2015 ACR/ARHP Annual Meeting
Longitudinal Observation of Psychological Factors and Health-Related Quality of Life in Childhood-Onset Lupus
Catherine Donnelly¹, Jordan T. Jones², Ji Li³, Natoshia Cunningham⁴, Susmita Kashikar-Zuck⁵ and Hermine I. Brunner², ¹Internal Medicine, University of Cincinnati, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Peking Union Medical College Hospital, Beijing, China, ⁴Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset Lupus (cSLE) is associated with decreased Health-related Quality of Life (HRQoL), and disease activity measures are often unrelated to overall perception of health. The…
Abstract Number: 804 • 2015 ACR/ARHP Annual Meeting
Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients
Yiu Tak Leung¹, Kathleen E. Sullivan², Kelly Maurer³, Li Song⁴ and Lihua Shi³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: : Epigenetic changes have been described in systemic lupus erythematosus (SLE) and offer a potential explanation for the chronicity of disease. We previously found…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].